ClinicalTrials.gg
CompletedNCT06304467Updated Oct 20, 2026

CM for Patients With ALD After Liver Transplant

An interventional study of Contingency Management in Alcohol Use Disorder, Alcohol; Liver and Post Liver Transplant, sponsored by Arpan A. Patel, MD. Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Arpan A. Patel, MD · Not applicable, Interventional, and Treatment

How we know · 2 judgments

Updated Oct 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,076 studies in Alcoholism with a site in United States — 190 open to participants now, 230 under way, 16 of them phase 3. Alcoholism · United States.

Enrollment
899th of 992
10 · median 80
Started
2024
with 58 others
No phase
436 of 1,076
85 open now
Registered
929th of 1,076
by date

Among the 1,076 studies in Alcoholism with a site in United States, this one is the 899th largest by enrollment of the 992 interventional ones that give a count, is one of 59 that started in 2024, is one of 436 with no phase, and was the 929th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

190 of the 1,076 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:

185 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,076 studies in Alcoholism with a site in United States, or all of them as a file.
02

Study summary

Alcohol associated liver disease (ALD) refers to liver injury, such as cirrhosis, that is caused by alcohol use. It affects 2 million adults in the U.S. and is now the leading cause of cirrhosis-related hospitalizations, cirrhosis- related deaths, and liver transplantation. Alcohol use disorder (AUD), the root cause of ALD, affects 15 million Americans each year. While research studies have shown that behavioral therapy and medications specific for alcohol use have helped people overcome their alcohol use disorder, there has not been enough information related to how successful these treatments are specifically for people with ALD. This study will look at a behavioral treatment called "contingency management" (CM) that has shown to be effective with people with other substance use disorders. CM is based on the principles of operant conditioning that involves offering prize-based or monetary incentives to patients with substance use disorders to reduce substance use. This study will look at the efficacy and acceptability of CM in patients who received a liver transplant and have evidence of recurrent alcohol use.

The proposed study is a pilot randomized controlled trial of 30 patients with ALD who received a liver transplant; 15 will be randomized to receive a 10-week CM intervention while 15 will receive treatment as usual (TAU or control). Subjects will be asked to complete 12 study visits (including Screening and Baseline Visits) that will last 1 to 2 hours each depending on the visit. All visits will be completed via Zoom or by phone. Study staff will instruct participants on how to use Zoom, if necessary. During the Screening and Baseline Visits, subjects will be: 1) asked to provide a urine test and blood draw, 2) complete the SCID-5 AUD, a semi-structured interview guide for making the major DSM-5 diagnoses, 3) complete the Iowa Gambling Test which looks at decision-making skills, 4) complete a survey that looks at the subject's quality of life after liver transplant, 4) review how much alcohol the subject has consumed in the last 30 days, 5) and if the subject has received any current AUD treatments. Once the Screening and Baseline visits are completed, subjects will be randomized to either the CM group or the TAU group. During the weekly visits, subjects will be asked to provide blood and urine samples and will be asked if they have had any alcohol since their last visit. All subjects will receive $20 for completing the visits. For those in the CM group, subjects will also receive a CM reward for negative urine and/or blood tests, depending on which results we receive first-with rewards ranging from $5 to $80 depending on the week. Additionally, during weeks 1, 5, and 10, those in the CM group will also complete the Client Satisfaction Questionnaire-8 to assess client satisfaction with CM and complete a semi-structured interview about the CM protocol as well as CM acceptability and feasibility.

Read the detailed description

This study is a pilot randomized controlled trial of 30 patients with ALD who received a liver transplant; 15 will be randomized to receive a 10-week CM intervention while 15 will receive treatment as usual (control).

Subjects will be recruited directly by research staff as well through MyChart messages.

For in-clinic subjects: Subjects will be identified by the RA via EMR review of patients listed for the day's clinic. Once identified, the Co-Investigator will approach the patient during the outpatient clinic visit with the recruitment flyer. The Co-Investigator will inform the participant that they may be eligible for the study. They will ask patients if the RA may contact them via phone to explain the study in more detail and/or answer any questions the subject may have after reviewing the flyer. If the subject agrees to be contacted, the Co-investigator will notify the RA and let the RA know that the subject has provided consent to contact. The RA will only contact the subject if the Co-Investigator has indicated the subject has provided permission to contact him or her. If the subject has declined permission for contact, the RA will not contact the subject, either by phone or other communication.

Alternatively, the RA may also approach potential subjects identified in clinic. The RA will provide the study flyer, explain the study in detail, and answer any questions the subject may have. If the subject voices interest in participating in the study, the RA can schedule the Consent and Baseline Visit that is mutually agreeable for the subject and RA. The RA will provide study contact information to the subject in case he or she needs to reschedule, or if any issues arise.

Identification by Clinical Staff: The PI will send quarterly emails to the clinical staff of the post-liver transplant clinics which includes physicians, nurse practitioners, social workers, and staff nurses. The email includes a brief summary of the study and the Eligibility Criteria. If the clinical staff have identified any potential subjects, they will email the PI or research assistant who will review the subject's electronic medical record to confirm eligibility. Once screened, the RA will send a MyChart message to the potential subject with study details and study contact information. If the subject is interested in the study and responds to the MyChart message through MyChart, by email, or by phone, then the RA will schedule the Consent and Baseline Visit according to the protocol.

MyChart Messages:

The study team will work with Care Connect analysts to create a work bench report that will identify patients that meet study criteria and the patients on the report will be sent a MyChart Recruitment message. The UCLA Embedded Clinical Research and Innovation (ECRI) team will run the workbench report and send out the messages. Only if the patient replies back with interest will the study team have access to their identifying information to contact them. The research assistant will review the subject's electronic medical record to confirm eligibility. Once screened, the RA will contact the potential subject via MyChart with more details about the study and to ask if they may contact them over the phone to discuss the study and answer any questions they may have. If they respond via MyChart that the RA may contact him or her, the RA will contact them via phone to explain the study, answer any questions, and if the subject is interested, schedule the Consent and Baseline Visit according to the protocol.

After written consent is obtained, the RA will confirm eligibility criteria:

If eligibility is confirmed and signed off by the PI, the participant will complete Baseline Visit activities via Zoom:

  1. Record socio-demographic data (self-reported demographics, behavior, and health data) and locator form
  2. Complete the Iowa Gambling Task
  3. Complete Structured Clinical Interview-5 for AUD (SCID-5 AUD), a semi-structured interview guide for making the major DSM-5 diagnoses
  4. Urine sample for EtG
  5. Blood draw for PeTH
  6. Complete Timeline Followback (TLFB), a validated instrument to assess amounts of drinking within the last 30 days
  7. Record concurrent AUD treatment strategies and therapies
  8. Complete Patient-Reported Outcomes Measurement Information System (PROMIS), to assess patient's quality of life after liver transplantation. The psychometric properties of this instrument have been previously validated in patients who have received a liver transplant.
  9. Randomize participant to contingency management (CM) or treatment as usual (TAU). Participants will be randomly assigned to either the CM treatment group or the TAU group (control) using a SAS® randomization software. Participants will be stratified by applying SCID-5-AUD criteria (groups will be mild or moderate/severe).

All participants will receive a $20 gift card for completing this visit, regardless of treatment arm.

After the initial visit, participants will attend weekly Zoom visits for 10 weeks and will complete assessments according to the protocol. At Visit 2, Visit 5, and Visit 10, participants will also undergo audio recorded semi-structured interviews about the CM protocol as well as CM acceptability and feasibility interviews with the research team. After these interviews, the audio-recordings will be analyzed as part of the study's first aim to look at the acceptability and feasibility of CM in the ALD population.

Since all weekly visits will be completed via Zoom or phone, participants will need to provide blood and urine samples at the nearest UCLA lab before their next weekly visit. CM rewards will not be provided until the study team receives the lab results for that week.

All participants will be compensated for completing each study visit with a gift card regardless of their randomization group. For those in the CM group, participants will also receive a CM reward for negative urine (EtG) and/or blood tests (PeTH), depending on which results are received first. Because PeTH can be elevated for several weeks after a positive test, a lower PeTH value in a subsequent week of checking will be considered a "negative" result, per previous studies. Additionally, if participants in the CM group have negative urine and/or blood test for 2 consecutive weeks, participants will receive a CM bonus.

The primary outcome for the study is the number of non-drinking days, which will be assessed by objective measures (i.e., presence of alcohol biomarkers in the blood and urine), as well as subjective measures (i.e., Timeline Followback). These assessments will be completed weekly. For the 10-week CM intervention, there will be a maximum of 70 non-drinking days.

Secondary outcomes include:

  • Health-related quality of life will be assessed using the Patient-Reported Outcomes Measurement Information System at the beginning and end of the intervention,
  • Acceptability of the intervention will be assessed with the Client Satisfaction Questionnaire-8 (CSQ-8) with a mean score of 24 (scale: 8-32) which will be considered acceptable, based on prior pilot interventions for AUD, and
  • Feasibility of the intervention will be assessed by calculating rates of recruitment and retention throughout the study period.

We will also obtain qualitative descriptions of acceptability and feasibility through individual, semi-structured interviews conducted with all 15 participants in the CM arm during three specific time points (V1, V5, V10).

03

Conditions studied

  • Alcohol Use Disorder
  • Alcohol; Liver
  • Post Liver Transplant
  • Contingency Management
  • Alcohol Liver Disease

Keywords

  • Alcohol Liver Disease
  • Contingency Management
  • Post Liver Transplant
  • Alcohol Use Disorder
  • Post Liver Transplant Drinking
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects 18 years of age or older
  • Have received a liver transplant
  • Has documented return to drinking (subjective or objective) within the past 60 days
  • Willing to partake in behavioral treatment for AUD
  • Written and ability for subject to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Current treatment for another substance use disorder
  • Unwilling to partake in behavioral treatment for AUD
  • Unwilling to provide written
  • Non-English speaking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • No intervention
    Treatment As Usual (TAU)

    Study Subjects randomized to treatment as usual (TAU) will not receive an intervention. They will continue with follow-up visits in the outpatient clinic as part of standard of care. .

  • Experimental
    Contingency Management (CM)

    Study subjects who have received a liver transplant and have been randomized to the treatment arm will receive contingency management, a positive reinforcement behavioral treatment with escalating rewards for consecutive either negative urine and blood tests (or lower value of metabolites than the previous week for PeTH) depending on which results are received first, capped at a maximum of $80 (in the form of a gift card) at the week 10 visit.

    Behavioral: Contingency Management

Interventions

  • BehavioralContingency Management

    Study subjects who have received a liver transplant and have been randomized to the treatment arm will receive contingency management, a positive reinforcement behavioral treatment with escalating rewards for consecutive either negative urine and blood tests (or lower value of metabolites than the previous week for PeTH) depending on which results are received first, capped at a maximum of $80 (in the form of a gift card) at the week 10 visit.

06

What researchers measure

Primary outcomes

  1. Number of Non-Drinking Days

    The primary outcome for the study is the number of non-drinking days, which will be assessed by objective measures (i.e., presence of alcohol biomarkers in the blood and urine), as well as subjective measures (i.e., Timeline Followback). For the 10-week CM intervention, there will be a maximum of 70 non-drinking days.

    Time frame: 10 Weeks

Secondary outcomes

  1. Patient-Reported Outcomes Measurement Information System (PROMIS® 29+2 Profile v2.1 (PROPr))

    To assess health related quality of life. The PROMIS-29 v2.0 profile assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain.

    Time frame: 10 Weeks

  2. Client Satisfaction Questionnaire-8.

    To assess acceptability of the CM program. An overall score is calculated by summing the respondent's rating (item rating) score for each scale item. For the CSQ-8 version, scores therefore range from 8 to 32, with higher values indicating higher satisfaction.

    Time frame: 10 Weeks

07

Study locations

1 site
  • Pfleger Liver Institute
    Los Angeles, California 90095-1406, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in May 2026, 19 months.

Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's 19 months is below that.

Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jun 2026 → May 2026 and completion Sep 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2024
First posted
Mar 12, 2024
StartActual
Sep 17, 2024
Primary completionActual
May 1, 2026was Jun 2026
CompletionActual
May 1, 2026was Sep 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 20, 2026
Primary completion
Jun 1, 2026→May 1, 2026 (actual)
Oct 20, 2026
Study completion
Sep 1, 2026→May 1, 2026 (actual)
Oct 20, 2026
Enrollment
30 (estimated)→10 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Active, not recruiting→Completed
    Primary completion Jun 1, 2026→May 1, 2026 (now actual)
    Study completion Sep 1, 2026→May 1, 2026 (now actual)
    Enrollment 30 (estimated)→10 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06304467
Lead sponsor
Arpan A. Patel, MD
Responsible party
Arpan A. Patel, MD (Hepatologist, Assistant Professor, David Geffen School of Medicine at UCLA, University of California, Los Angeles) — Sponsor-investigator
First posted
Mar 12, 2024
Start date
Sep 17, 2024
Primary completion
May 1, 2026
Completion
May 1, 2026
Last update
Oct 20, 2026

Study contacts

Arpan G Patel, MD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion